Patient Leaflet Updated 02-Oct-2024 | Baxter Healthcare Ltd
Eribulin Baxter 0.44mg/ml solution for injection
Eribulin Baxter 0.44 mg/ml solution for injection
eribulin
1. What Eribulin Baxter is and what it is used for
2. What you need to know before you use Eribulin Baxter
3. How to use Eribulin Baxter
4. Possible side effects
5. How to store Eribulin Baxter
6. Contents of the pack and other information
Eribulin Baxter contains the active substance eribulin and is an anti-cancer medicine which works by stopping the growth and spread of cancer cells.
It is used in adults for locally advanced or metastatic breast cancer (breast cancer that has spread beyond the original tumour) when at least one other therapy has been tried but has lost its effect.
It is also used in adults for advanced or metastatic liposarcoma (a type of cancer that arises from fat tissue) when previous therapy has been tried but has lost its effect.
Talk to your doctor or nurse before using Eribulin Baxter:
If any of these affects you, tell your doctor who may wish to stop treatment or reduce the dose.
Do not give this medicine to children between the ages of 0 to 18 years because it does not work.
Tell your doctor if you are using, have recently used or might use any other medicines.
Eribulin Baxter may cause serious birth defects and should not be used if you are pregnant unless it is thought clearly necessary after carefully considering all the risk to you and the baby. It may also cause future permanent fertility problems in men if they take it and they should discuss this with their doctor before starting treatment. Women of childbearing age should use effective contraception during and up to 3 months after treatment with Eribulin Baxter.
Eribulin Baxter must not be used during breast-feeding because of the possibility of risk to the child.
Eribulin Baxter may cause side effects such as tiredness (very common) and dizziness (common). Do not drive or use machines if you feel tired or dizzy.
This medicine contains 78.9 mg (0.1 mL) of ethanol anhydrous in each vial. The amount in 2 mL of this medicine is equivalent to 2 mL beer or less than 1 mL wine. The small amount of alcohol in this medicine will not have any noticeable effects.
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially `sodium-free'.
Eribulin Baxter will be given to you by a qualified healthcare professional as an injection into a vein, over a period of 2 to 5 minutes. The dose you will receive is based on your body surface area (expressed in squared metres, or m²) which is calculated from your weight and height. The usual dose of Eribulin Baxter is 1.23 mg/m², but this may be adjusted by your doctor based on your blood test results or other factors. To ensure that the whole dose of Eribulin Baxter is given it is recommended that a saline solution is flushed into the vein after Eribulin Baxter is given.
Eribulin Baxter is usually given on Days 1 and 8 of every 21-day cycle. Your doctor will determine how many cycles of treatment you should receive. Depending on the results of your blood tests, the doctor may need to delay administration of the medicine until the blood tests return to normal. The doctor may also then decide to reduce the dose you are given.
If you have any further questions about the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Eribulin Baxter and seek medical attention straight away if you experience any of the following serious symptoms:
Very common side effects (may affect more than 1 in 10 people) are:
Common side effects (may affect up to 1 in 10 people) are:
Uncommon side effects (may affect up to 1 in 100 people) are:
Rare side effects (may affect up to 1 in 1000 people) are:
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.
Store below 30°C.
If Eribulin Baxter is diluted for infusion:
Chemical and physical in-use stability of the diluted solution has been demonstrated for 24 hours at 15-25°C and 72 hours at 2°C -8°C.
From a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C -8°C, unless dilution has taken place in controlled and validated aseptic conditions.
If Eribulin Baxter as an undiluted solution has been transferred into a syringe:
Chemical and physical in-use stability of the undiluted solution in a syringe has been demonstrated for 4 hours at 15-25°C and 24 hours at 2°C -8°C.
Eribulin Baxter vials are for single-use only. Discard unused portions of Eribulin Baxter.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Eribulin Baxter is a clear, colourless aqueous solution for injection essentially free from visible particles provided in a glass vial containing 2 mL of solution. Each carton contains 1 vial.
Baxter is a registered trademark of Baxter International Inc.
This leaflet was last revised in April 2024
Detailed information on this medicine is available on the website of the UK Medicines and Healthcare products Regulatory Agency (MHRA)
Caxton Way, Thetford, Norfolk, IP24 3SE, UK
+44 (0)1635 206071
+44 (0)1635 206071
+44 (0)1635 206345
http://www.baxterhealthcare.co.uk